摘要
目的:观察丁苯酞联合依达拉奉右莰醇治疗腔隙性脑梗死患者的效果。方法:回顾性分析2021年1月至2023年10月该院收治的98例腔隙性脑梗死患者的临床资料,按照治疗方法不同将其分为研究组和对照组各49例。两组均进行基础治疗,在此基础上,对照组予以依达拉奉右莰醇治疗,研究组在对照组基础上联合丁苯酞治疗,两组均连续治疗14 d。比较两组临床疗效,治疗前后神经功能[美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)]评分、中枢神经特异性蛋白(S100β)水平、血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)]水平,以及不良反应发生率。结果:研究组治疗总有效率为89.80%(44/49),高于对照组的71.43%(35/49),差异有统计学意义(P<0.05);治疗后,两组NIHSS、mRS评分和S100β水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组NO水平均高于治疗前,且研究组高于对照组,两组ET-1水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丁苯酞联合依达拉奉右莰醇治疗腔隙性脑梗死患者可提高治疗总有效率,降低神经功能评分和S100β水平,改善血管内皮功能指标水平,效果优于单纯依达拉奉右莰醇治疗。
Objective:To observe effects of Butylphthalide combined with Edaravone dextrogenol in treatment of patients with lacunar cerebral infarction.Methods:The clinical data of 98 patients with lacunar cerebral infarction admitted to this hospital from January 2021 to October 2023 were retrospectively analyzed.According to different treatment methods,they were divided into study group and control group,49 cases in each group.Both groups received basic treatment.On this basis,the control group was treated with Edaravone dextrogenol,while the study group was treated with Butylphthalide on the basis of that of the control group.Both groups were treated for 14 d.The clinical efficacy,the neurological function[National Institutes of Health stroke scale(NIHSS),modified Rankin scale(mRS)]score,the central nervous specific protein(S100β)level,the vascular endothelial function indexes[endothelin-1(ET-1),nitric oxide(NO)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 89.80%(44/49),which was higher than 71.43%(35/49)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS and mRS scores as well as the S100βlevels in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of NO in the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of ET-1 in the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Butylphthalide combined with Edaravone dextrogenol in the treatment of the patients with lacunar cerebral infarction can improve the total effective rate of treatment,reduce the neurological function scores and the S100βlevels,and improve the levels of vascular endothelial function indexes.Moreover,it is superior to simple Edaravone dextrogenol treatment.
作者
王瑞
崔慧琪
王艳艳
WANG Rui;CUI Huiqi;WANG Yanyan(Department of Neurology of Taikang County People’s Hospital,Zhoukou 475400 Henan,China)
出处
《中国民康医学》
2025年第8期17-19,共3页
Medical Journal of Chinese People’s Health
关键词
丁苯酞
依达拉奉右莰醇
腔隙性脑梗死
血管内皮功能
神经功能
不良反应
Butylphthalide
Edaravone dextrogenol
Lacunar cerebral infarction
Vascular endothelial function
Neurological function
Adverse reaction
作者简介
王瑞(1975.07-),女,汉族,河南太康人,本科,副主任医师,研究方向为神经内科。
